Gland Pharma shares surge over 6% after US FDA approval for breast cancer drug

By Aditya Bhagchandani Published on April 8, 2024, 11:33 IST

Shares of Gland Pharma surged over 6% following the company’s announcement of receiving approval from the United States Food and Drug Administration (USFDA) for its breast cancer drug,

Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial (Product).

In a statement released by the company, they expressed their excitement about this milestone achievement. The approved product is expected to be the first generic approval on the market, with plans for a near-term launch through its marketing partner.

Gland Pharma is co-developing several complex injectables, including Eribulin Mesylate, with Orbicular Pharmaceutical Technologies Private Limited.

As of 11:30 am, the shares of Gland Pharma were trading 6.65% higher at ₹1,871.25 on the National Stock Exchange (NSE).

Gland Pharma

Aditya Bhagchandani

Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.